NCT07100925View on ClinicalTrials.gov

A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

December 31, 2030

Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)Renal TransplantSolid TumorSolid Tumor Cancer
Interventions
DRUG

tolododekin alfa

IT administration of ANK-101 once every 3 weeks for 2 cycles, followed by surgical resection

Sponsors
All Listed Sponsors
lead

Ankyra Therapeutics, Inc

INDUSTRY